Cargando…

Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1/2 Genes Pathogenic Variants: Results from an Italian Survey

SIMPLE SUMMARY: Being a healthy carrier of a BRCA1/2 pathogenetic variant is not a contraindication to hormonal contraception and menopause hormonal therapy; however, insufficient knowledge on the topic frequently translates into suboptimal counseling and care. The results of this nationwide Italian...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massarotti, Claudia, Buonomo, Barbara, Dellino, Miriam, Campanella, Maria, De Stefano, Cristofaro, Ferrari, Alberta, Anserini, Paola, Lambertini, Matteo, Peccatori, Fedro A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315728/ https://www.ncbi.nlm.nih.gov/pubmed/35884518 http://dx.doi.org/10.3390/cancers14143457

Ejemplares similares

Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting
por: Buonomo, Barbara, et al.
Publicado: (2021)

Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy
por: Massarotti, C., et al.
Publicado: (2023)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

BRCA mutation carriers’ perceptions on postmenopausal hormone therapy: An Italian study
por: Grandi, Giovanni, et al.
Publicado: (2021)

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants
por: Lambertini, Matteo, et al.
Publicado: (2021)

The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows
por: Loizzi, Vera, et al.
Publicado: (2023)

Overview on population screening for carriers with germline BRCA mutation in China
por: Lei, Huijun, et al.
Publicado: (2022)

Healthcare Professional Communication on Sexual Health: A Report from the Italian Working Group on Adolescents and Young Adults with Cancer
por: Quarello, Paola, et al.
Publicado: (2023)

Re: Safety and efficacy concerns of long-acting GnRH agonist trigger for ovulation induction in oncological patients undergoing oocyte cryopreservation: a call for caution and further investigation
por: Massarotti, C., et al.
Publicado: (2023)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers
por: Lee, Young-Jae, et al.
Publicado: (2017)

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
por: Whittemore, A S, et al.
Publicado: (2004)

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits
por: Schrijver, Lieske H, et al.
Publicado: (2022)

Discussing motherhood when the oncological prognosis is dire: ethical considerations for physicians
por: Linkeviciute, Alma, et al.
Publicado: (2020)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2
por: Bernstein-Molho, Rinat, et al.
Publicado: (2022)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review
por: Anderson, Richard A, et al.
Publicado: (2022)

Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines
por: Dullens, Boudewijn, et al.
Publicado: (2020)

Can we trust tumour markers in pregnancy after breast cancer? A case of elevated CA 15-3 in the third trimester of pregnancy normalising after delivery
por: Buonomo, Barbara, et al.
Publicado: (2019)

Impact of Breast Cancer and Germline BRCA Pathogenic Variants on Fertility Preservation in Young Women
por: Prokurotaite, Elze, et al.
Publicado: (2023)

Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer
por: Huang, Xin, et al.
Publicado: (2020)

Vascular endothelium function among male carriers of BRCA 1&2 germline mutation
por: Witberg, Guy, et al.
Publicado: (2019)

Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences
por: Peccatori, Fedro Alessandro, et al.
Publicado: (2018)

Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group
por: Toss, Angela, et al.
Publicado: (2022)

Cancer and fertility preservation: international recommendations from an expert meeting
por: Lambertini, Matteo, et al.
Publicado: (2016)

BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile
por: Alvarez, Carolina, et al.
Publicado: (2017)

miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil
por: Pessôa-Pereira, Danielle, et al.
Publicado: (2020)

COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore
por: Zhang, Zewen, et al.
Publicado: (2023)

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
por: Metzger-Filho, Otto, et al.
Publicado: (2021)

Gastric neuroendocrine tumors in a BRCA2 germline mutation carrier: A case report
por: Zhang, Hui-Fang, et al.
Publicado: (2023)

Psychological issues and construction of the mother-child relationship in women with cancer during pregnancy: a perspective on current and future directions
por: Ferrari, Federica, et al.
Publicado: (2018)

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
por: Wang-Gohrke, S, et al.
Publicado: (1999)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
por: Gadducci, Angiolo, et al.
Publicado: (2019)

Uterine irradiation as a determinant of infertility and pregnancy losses in young cancer survivors
por: Buonomo, Barbara, et al.
Publicado: (2020)

Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations
por: Phillips, Kelly-Anne, et al.
Publicado: (2016)

Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience
por: Cassani, Chiara, et al.
Publicado: (2022)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells
por: Scaruffi, Paola, et al.
Publicado: (2019)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c0d34hca0n1nlr7uluac01ouq4